GENETIC ANALYSIS NK -60 Market Cap ($2.36 Million)
Market Cap & Net Worth: GENETIC ANALYSIS NK -60 (8V8)
GENETIC ANALYSIS NK -60 market cap. GENETIC ANALYSIS NK -60 (F:8V8) has a market capitalization of $2.36 Million (€2.02 Million) as of November 3, 2026. Listed on the F stock exchange, this Germany-based company holds position #29833 globally and #2581 in its home market, demonstrating a 1.32% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying GENETIC ANALYSIS NK -60's stock price €0.03 by its total outstanding shares 69087041 (69.09 Million). Also see 8V8 cash flow conversion for how efficiently the company converts equity into cash flow.
GENETIC ANALYSIS NK -60 Market Cap History (2021–2026)
GENETIC ANALYSIS NK -60 market cap history from 2021 to 2026. Data shows change from $48.70 Million to $2.49 Million (-48.67% CAGR). Check GENETIC ANALYSIS NK -60 stock price for real-time trading data and today's change.
GENETIC ANALYSIS NK -60 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how GENETIC ANALYSIS NK -60's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore GENETIC ANALYSIS NK -60 (8V8) equity growth momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.21x
GENETIC ANALYSIS NK -60's market cap is 0.21 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $48.70 Million | $6.80 Million | -$29.01 Million | 7.16x | N/A |
| 2022 | $13.38 Million | $11.16 Million | -$28.27 Million | 1.20x | N/A |
| 2023 | $4.35 Million | $14.15 Million | -$23.82 Million | 0.31x | N/A |
| 2024 | $1.83 Million | $15.89 Million | -$14.77 Million | 0.11x | N/A |
| 2025 | $3.43 Million | $16.71 Million | -$11.41 Million | 0.21x | N/A |
Competitor Companies of 8V8 by Market Capitalization
Companies near GENETIC ANALYSIS NK -60 in the global market cap rankings as of November 3, 2026. Also see GENETIC ANALYSIS NK -60 asset portfolio for a full breakdown of the balance sheet.
Key companies related to GENETIC ANALYSIS NK -60 by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #87 globally with a market cap of $224.59 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #143 globally with a market cap of $161.03 Billion USD.
- Natera Inc (NASDAQ:NTRA): Ranked #493 globally with a market cap of $54.62 Billion USD.
- WuXi AppTec Co Ltd (SHG:603259): Ranked #539 globally with a market cap of $50.18 Billion USD ( CN¥342.92 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #87 | Thermo Fisher Scientific Inc | NYSE:TMO | $224.59 Billion | $682.65 |
| #143 | Danaher Corporation | NYSE:DHR | $161.03 Billion | $227.97 |
| #493 | Natera Inc | NASDAQ:NTRA | $54.62 Billion | $378.92 |
| #539 | WuXi AppTec Co Ltd | SHG:603259 | $50.18 Billion | CN¥138.65 |
Market Capitalization of GENETIC ANALYSIS NK -60 (2021–2026)
Market capitalization of GENETIC ANALYSIS NK -60 from 2021 to today. Between 2021 and today, GENETIC ANALYSIS NK -60's market cap moved from $48.70 Million to $ 2.49 Million, with a yearly change of -48.67%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €2.49 Million | -27.53% |
| 2025 | €3.43 Million | +88.05% |
| 2024 | €1.83 Million | -57.99% |
| 2023 | €4.35 Million | -67.51% |
| 2022 | €13.38 Million | -72.54% |
| 2021 | €48.70 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of GENETIC ANALYSIS NK -60 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.36 Million USD |
| MoneyControl | $2.36 Million USD |
| MarketWatch | $2.36 Million USD |
| marketcap.company | $2.36 Million USD |
| Reuters | $2.36 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About GENETIC ANALYSIS NK -60
Genetic Analysis AS, a science-based diagnostic company, engages in the research, development, manufacturing, and sale of diagnostic test solutions for human microbiome in the United States, Europe, and internationally. The company offers GA-map MHI Gut Health Test, a microbiome-based diagnostic test for antibiotic-induced microbiome imbalances; GA-map Dysbiosis Test, a diagnostic microbiome test… Read more